Follow
Andrew Erickson
Title
Cited by
Cited by
Year
Spatially resolved clonal copy number alterations in benign and malignant tissue
A Erickson, M He, E Berglund, M Marklund, R Mirzazadeh, N Schultz, ...
Nature 608 (7922), 360-367, 2022
1002022
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ...
Nature communications 12 (1), 5307, 2021
672021
Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy
K Lahdensuo, A Erickson, I Saarinen, H Seikkula, J Lundin, M Lundin, ...
Modern Pathology 29 (12), 1565-1574, 2016
562016
PTEN loss but not ERG expression in diagnostic biopsies is associated with increased risk of progression and adverse surgical findings in men with prostate cancer on active …
U Lokman, AM Erickson, H Vasarainen, AS Rannikko, T Mirtti
European urology focus 4 (6), 867-873, 2018
512018
New prostate cancer grade grouping system predicts survival after radical prostatectomy
A Erickson, K Sandeman, K Lahdensuo, S Nordling, M Kallajoki, ...
Human pathology 75, 159-166, 2018
302018
Repeat multiparametric MRI in prostate cancer patients on active surveillance
JT Eineluoto, P Järvinen, A Kenttämies, TP Kilpeläinen, H Vasarainen, ...
PloS one 12 (12), e0189272, 2017
302017
Fibroblast as a critical stromal cell type determining prognosis in prostate cancer
S Blom, A Erickson, A Östman, A Rannikko, T Mirtti, O Kallioniemi, ...
The Prostate 79 (13), 1505-1513, 2019
282019
Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy
JK Björk, I Ahonen, T Mirtti, A Erickson, A Rannikko, A Bützow, S Nordling, ...
Oncotarget 9 (58), 31200, 2018
272018
Morphological Features Extracted by AI Associated with Spatial Transcriptomics in Prostate Cancer
E Chelebian, C Avenel, K Kartasalo, M Marklund, A Tanoglidi, T Mirtti, ...
Cancers 13 (19), 4837, 2021
222021
Enzalutamide-induced feed-forward signaling loop promotes therapy-resistant prostate cancer growth providing an exploitable molecular target for Jak2 inhibitors
V Udhane, C Maranto, DT Hoang, L Gu, A Erickson, S Devi, PG Talati, ...
Molecular cancer therapeutics 19 (1), 231-246, 2020
222020
A systematic review of prostate cancer heterogeneity: Understanding the clonal ancestry of multifocal disease
A Erickson, A Hayes, T Rajakumar, C Verrill, RJ Bryant, FC Hamdy, ...
European urology oncology 4 (3), 358-369, 2021
212021
Ductal adenocarcinoma of the prostate: a systematic review and meta‐analysis of incidence, presentation, prognosis, and management
N Ranasinha, A Omer, Y Philippou, E Harriss, L Davies, K Chow, ...
BJUI compass 2 (1), 13-23, 2021
202021
Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005–2013: a population-based analysis
K Lahdensuo, A Rannikko, VJ Anttila, A Erickson, A Pätäri-Sampo, ...
Prostate cancer and prostatic diseases 19 (4), 417-422, 2016
152016
Positive STAT5 protein and locus amplification status predicts recurrence after radical prostatectomy to assist clinical precision management of prostate cancer
BR Haddad, A Erickson, V Udhane, PS LaViolette, JD Rone, MA Kallajoki, ...
Cancer Epidemiology, Biomarkers & Prevention 28 (10), 1642-1651, 2019
132019
Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer
B Ozbek, O Ertunc, A Erickson, ID Vidal, C Gomes‐Alexandre, G Guner, ...
The Prostate 82 (6), 706-722, 2022
122022
Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy
K Sandeman, JT Eineluoto, J Pohjonen, A Erickson, TP Kilpeläinen, ...
Plos one 15 (7), e0235779, 2020
112020
Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer
K Sopyllo, AM Erickson, T Mirtti
Cancers 13 (4), 628, 2021
92021
Transcript analysis of commercial prostate cancer risk stratification panels in hard‐to‐predict grade group 2–4 prostate cancers
TPK Lehto, C Stürenberg, A Malén, AM Erickson, H Koistinen, IG Mills, ...
The Prostate 81 (7), 368-376, 2021
72021
The spatial landscape of clonal somatic mutations in benign and malignant tissue
A Erickson, E Berglund, M He, M Marklund, R Mirzazadeh, N Schultz, ...
bioRxiv, 2021
72021
PP2A methylesterase PME‐1 suppresses anoikis and is associated with therapy relapse of PTEN‐deficient prostate cancers
A Aakula, A Isomursu, C Rupp, A Erickson, N Gupta, O Kauko, P Shah, ...
Molecular Oncology, 2023
62023
The system can't perform the operation now. Try again later.
Articles 1–20